API dispersal through hot melt extrusion
It has been estimated that 40–60% of drugs in development have poor bioavailability due to low aqueous solubility. This percentage is likely to increase in the future with the increased use of combinatorial chemistry in drug discovery targeting lipophilic receptors. Poor bioavailability results in increased development times, decreased efficacy, increased inter- and intrapatient variability and side-effects, and higher dosages that reduce patient compliance and increase cost. Thus, the ability to improve drug solubility and hence bioavailability through formulation and process technology is critical to improving a drug product’s efficacy and safety and reducing its cost.